Multi-marker Companion Diagnostics - Significantly improving oncology drug targeting and saving oncology drugs that have failed Phase III
Clinical Persona develops multi-gene companion diagnostic signatures for cancer drugs. The signatures help direct the drugs to patients most likely to benefit from them. One application of our signatures is rescuing drugs that failed a Phase III trial. Other applications are pre-clinical and Phase III signatures, which have the potential to significantly de-risk cancer drug development. Our customers are companies developing cancer drugs.